Thermo Fisher beats expectations in Q2
This article was originally published in Clinica
Thermo Fisher Scientific reported second-quarter revenues of $3.24bn (+4% year-on-year) and adjusted earnings of $1.32 per share (+8%), beating analyst consensus of $3.22bn and $1.30, respectively. The firm lowered its revenue guidance to $12.83-12.95bn (from $12.84-13.00bn) on foreign exchange headwinds; but upped the lower end of its EPS guidance to $5.29-5.39 (from $5.27-5.39). “Management continues to execute well in a challenging environment via share gains and solid cost controls,” noted Goldman Sachs analyst Isaac Ro. Meanwhile, Jefferies analyst Brandon Couillard raised his share price target to $102, from $95. The firm’s stock is currently trading at around $90.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.